NCT02115984 is a Phase 2 clinical trial of Panagen in Breast Cancer, sponsored by Panagen, Limited Liability Company.

Who is sponsoring NCT02115984?

NCT02115984 is sponsored by Panagen, Limited Liability Company.

What drugs are being tested in NCT02115984?

Interventions in NCT02115984: Panagen, Placebo, Chemotherapy.

What condition does NCT02115984 study?

NCT02115984 studies Breast Cancer.

Is NCT02115984 still recruiting?

NCT02115984 is currently completed. Last updated 11 June 2014.

Are results published for NCT02115984?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2014-06-11 · How we verify

NCT02115984

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Double-blind Multicenter Placebo-controlled Study of the Safety and Leukostimulatory Activity of the Preparation "Panagen" in Patients With Breast Cancer

Completed Phase 2 Results posted Last updated 11 June 2014

What this trial tests

Phase 2 trial testing Panagen in Breast Cancer in 80 participants. Completed in 1 May 2012.

Timeline

1 May 2010

Primary endpoint
1 May 2012

1 May 2012

Quick facts

Lead sponsor	Panagen, Limited Liability Company
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	80
Start date	1 May 2010
Primary completion	1 May 2012
Estimated completion	1 May 2012

Drugs / interventions tested

Panagen — full drug profile →
Placebo
Chemotherapy (chemotherapy) — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Panagen, Limited Liability Company — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The Quantity of Leukocytes and Neutrophils in the Blood of Patients
Time frame: Baseline, Day 21 after 2nd chemotherapy (Day 42 post-baseline), Day 21 after 3rd chemotherapy (Day 63 post-baseline)

Sponsor's own description

The goal of this trial is to assess the safety, therapeutic dose, and leukostimulatory activity of the preparation Panagen in the therapeutic schemes for treating cancer diseases in the patients receiving a standard chemotherapy for breast cancer of stages II-IV (with distant metastases).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.
Proskurina AS, Gvozdeva TS, Alyamkina EA, Dolgova EV, et al · · 2015 · cited 4× · PMID 25886605 · DOI 10.1186/s12885-015-1142-z
Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.
Proskurina AS, Gvozdeva TS, Potter EA, Dolgova EV, et al · · 2016 · cited 3× · PMID 27538465 · DOI 10.1186/s12885-016-2711-5

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02115984 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Panagen, Limited Liability Company
Last refreshed: 11 June 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02115984.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing